StockNews.com began coverage on shares of ChromaDex (NASDAQ:CDXC – Get Rating) in a report published on Thursday morning. The firm issued a buy rating on the stock.
Separately, HC Wainwright cut their price objective on ChromaDex from $5.50 to $5.00 and set a buy rating for the company in a report on Monday, March 13th.
ChromaDex Stock Down 3.1 %
Shares of CDXC opened at $1.58 on Thursday. ChromaDex has a one year low of $1.15 and a one year high of $2.99. The business has a fifty day moving average of $1.83 and a 200 day moving average of $1.64.
Institutional Trading of ChromaDex
Several hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its holdings in ChromaDex by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 558,849 shares of the company’s stock valued at $938,000 after purchasing an additional 5,524 shares during the period. Cambridge Investment Research Advisors Inc. grew its holdings in ChromaDex by 5.9% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 126,558 shares of the company’s stock valued at $213,000 after purchasing an additional 7,000 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in ChromaDex by 74.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,300 shares of the company’s stock valued at $66,000 after purchasing an additional 16,800 shares during the period. International Assets Investment Management LLC bought a new stake in ChromaDex during the fourth quarter valued at about $34,000. Finally, Oppenheimer & Co. Inc. grew its holdings in ChromaDex by 127.3% during the second quarter. Oppenheimer & Co. Inc. now owns 39,110 shares of the company’s stock valued at $65,000 after purchasing an additional 21,900 shares during the period. Institutional investors own 42.81% of the company’s stock.
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
- Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.